Program
Aminolevulinic Acid
Also written as “Aminolevulinic Acid (ALA)”, “5 Aminolevulinic Acid” and “PD P 506 A”.
Its studies are mostly in Keratosis, Actinic · Glioma · Glioblastoma · Breast Neoplasms · Malaria, led by 10 companies.
Drug pageAminolevulinic Acid: every studyMany companies study it; this page follows only the 22 they lead. All 114 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sun Pharmaceutical Industriesits history only | 100 open or running | phase 3since May 7, 2014 | Jun 24, 2008 | none ahead |
| Alpheus Medicalits history only | 21 open or running | phase 1since May 2, 2022 | May 2, 2022 | Oct 30, 2027phase 1 · NCT07862647 |
| medacits history only | 20 open or running | phase 3since Oct 18, 2005 | Oct 18, 2005 | none ahead |
| photonamic GmbH & Co. KGits history only | 20 open or running | phase 2since Jul 11, 2018 | Jul 11, 2018 | none ahead |
| Hemerion Therapeuticsits history only | 11 open or running | phase 2since Feb 8, 2023 | Feb 8, 2023 | none ahead |
| Lee's Pharmaceutical | 11 open or running | phase 3since Nov 27, 2023 | Nov 27, 2023 | Dec 2027phase 3 · NCT06160492 |
| Neopharma Japanits history only | 10 open or running | phase 2since Jul 12, 2019 | Jul 12, 2019 | none ahead |
| Nobelpharmaits history only | 10 open or running | phase 3since Jul 16, 2010 | Jul 16, 2010 | none ahead |
| SBI ALApharma Canadaits history only | 10 open or running | phase 3since Mar 22, 2021 | Mar 22, 2021 | none ahead |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceuticalits history only | 10 open or running | phase 3since May 12, 2024 | May 12, 2024 | none ahead |
Also a collaborator on its studies: Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Lee's Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2015Named aminolevulinic acidINNProposed as its International Nonproprietary Name in WHO's List 114
- Nov 27, 2023First study: phase 3 study in GliomaFirst studyNCT06160492 · 79 planned · China
- Oct 27, 2026Primary completion moved from 2026-02 to 2027-12Date moved laterphase 3 · +22 months · NCT06160492
Ahead
- Dec 2027Primary completion: phase 3 study in GliomaNCT06160492
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Lee's Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06160492Glioma · China | 3 | Recruiting | Dec 2027 | 79 |
How it is read
Names in the registry
- “Aminolevulinic Acid (ALA)”, 3 entries
- “5 Aminolevulinic Acid”, 2 entries
- “PD P 506 A”, 2 entries
- “Aminolevulinic Acid”, 2 entries
- “ALA”, 2 entries
Conditions, from the studies’ own filings
- Keratosis, Actinic, 10 studies
- Glioma, 3 studies
- Glioblastoma, 3 studies
- Breast Neoplasms, 1 study
- Malaria, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.